Amelioration of operation-induced suppression of marginating pulmonary NK activity using poly IC: A potential approach to reduce postoperative metastasis

Annals of Surgical Oncology

Volumn 14, Issue 2, 2007, Pages 841-852

  Shakhar, Guy ^a   Abudarham, Naphtali ^b   Melamed, Rivka ^b   Schwartz, Yossi ^b   Rosenne, Ella ^b   Ben Eliyahu, Shamgar ^b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Lung; Neuroimmunology; NK cells; Rodents; Tumor Immunology

Indexed keywords

CORTICOSTERONE; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL ACTIVITY; CONTROLLED STUDY; CYTOTOXICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LAPAROTOMY; LEUKOCYTE; LOW DRUG DOSE; LUNG METASTASIS; LYMPHOCYTE; MALE; NATURAL KILLER CELL; NONHUMAN; RAT; RISK;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CORTICOSTERONE; DINOPROSTONE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERFERON INDUCERS; KILLER CELLS, NATURAL; LAPAROTOMY; LUNG; LUNG NEOPLASMS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; NEOPLASM METASTASIS; POLY I-C; POSTOPERATIVE COMPLICATIONS; RATS; RATS, INBRED F344; TUMOR ESCAPE;

EID: 33846633686     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-006-9078-9     Document Type: Article

References (41)

1. Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003; 10(8):972-992.
2. Sietses C, Wiezer MJ, Eijsbouts QA, et al. A prospective randomized study of the systemic immune response after laparoscopic and conventional Nissen fundoplication. Surgery 1999; 126(1):5-9.
3. Munford RS, Pugin J. Normal responses to injury prevent systemic inflammation and can be immunosuppressive. Am J Respir Crit Care Med 2001; 163(2):316-321.
4. Woiciechowsky C, Schoning B, Lanksch WR, et al. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med 1999; 77(11):769-780.
5. Morton DL, Ollila DW, Hsueh EC, et al. Cytoreductive surgery and adjuvant immunotherapy: a new management paradigm for metastatic melanoma. CA Cancer J Clin 1999; 49(2):101-116; 65.
6. Carter JJ, Whelan RL. The immunologic consequences of laparoscopy in oncology. Surg Oncol Clin N Am 2001; 10(3):655-677.
7. Ben-Eliyahu S, Page GG, Yirmiya R, Taylor AN. Acute alcohol intoxication suppresses natural killer cell activity and promotes tumor metastasis. Nat Med 1996; 2(4):457-460.
8. Barlozzari T, Leonhardt J, Wiltrout RH, et al. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 1985; 134(4):2783-2789.
9. Shakhar G, Ben-Eliyahu S. In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 1998; 160(7):3251-3258.
10. Ben-Eliyahu S, Page GG. In vivo assessment of natural killer cell activity in rats. Prog Neuroendocrineimmunol 1992; 5:199-214.
11. Shingu K, Helfritz A, Kuhlmann S, et al. Kinetics of the early recruitment of leukocyte subsets at the sites of tumor cells in the lungs: natural killer (NK) cells rapidly attract monocytes but not lymphocytes in the surveillance of micrometastasis. Int J Cancer 2002; 99(1):74-81.
12. Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999; 80(6):880-888.
13. Page GG, Blakely WP, Ben-Eliyahu S. Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats. Pain 2001; 90(1-2):191-199.
14. Bar-Yosef S, Melamed R, Page GG, et al. Attenuation of the tumor-promoting effect of surgery by spinal blockade in rats. Anesthesiology 2001; 94(6):1066-1073.
15. Melamed R, Bar-Yosef S, Shakhar G, et al. Suppression of natural killer cell activity and promotion of tumor metastasis by ketamine, thiopental, and halothane, but not by propofol: mediating mechanisms and prophylactic measures. Anesth Analg 2003; 97(5):1331-1339.
16. Ben-Eliyahu S, Shakhar G, Rosenne E, et al. Hypothermia in barbiturate-anesthetized rats suppresses natural killer cell activity and compromises resistance to tumor metastasis: a role for adrenergic mechanisms. Anesthesiology 1999; 91(3):732-740.
17. Melamed R, Rosenne E, Shakhar K, et al. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: suppression by surgery and the prophylactic use of a beta-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 2005; 19(2):114-126.
18. Shakhar G, Blumenfeld B. Glucocorticoid involvement in suppression of NK activity following surgery in rats. J Neuroimmunol 2003; 138(1-2):83-91.
19. Berguer R, Bravo N, Bowyer M, et al. Major surgery suppresses maximal production of helper T-cell type 1 cytokines without potentiating the release of helper T-cell type 2 cytokines. Arch Surg 1999; 134(5):540-544.
20. Leung KH, Koren HS. Regulation of human natural killing. II. Protective effect of interferon on NK cells from suppression by PGE2. J Immunol 1982; 129(4):1742-1747.
21. Sone S, Fidler IJ. Activation of rat alveolar macrophages to the tumoricidal state in the presence of progressively growing pulmonary metastases. Cancer Res 1981; 41(6):2401-2406.
22. Shakhar G, Bar-Ziv I, Ben-Eliyahu S. Diurnal changes in lung tumor clearance and their relation to NK cell cytotoxicity in the blood and spleen. Int J Cancer 2001; 94(3):401-406.
23. Ben-Eliyahu S, Page GG, Shakhar G, Taylor AN. Increased susceptibility to metastasis during pro-oestrus/oestrus in rats: possible role of oestradiol and natural killer cells. Br J Cancer 1996; 74(12):1900-1907.
24. Page GG, Ben-Eliyahu S, Liebeskind JC. The role of LGL/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine. Brain Beh Immun 1994; 8(3):241-250.
25. dim subpopulations of rat natural killer cells. J Immunol 1992; 148(11):3658-3665.
26. Chambers WH, Vujanovic NL, DeLeo AB, et al. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J Exp Med 1989; 169(4):1373-1389.
27. Hochman PS, Cudkowicz G. Different sensitivities to hydrocortisone of natural killer cell activity and hybrid resistance to parental marrow grafts. J Immunol 1977; 119(6):2013-2015.
28. Brunda MJ, Herberman RB, Holden HT. Inhibition of murine natural killer cell activity by prostaglandins. J Immunol 1980; 124(6):2682-2687.
29. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll- like receptor 3. Nature 2001; 413(6857):732-738.
30. Senik A, Gresser I, Maury C, et al. Enhancement by interferon of natural killer cell activity in mice. Cell Immunol 1979; 44(1):186-200.
31. Lee CK, Rao DT, Gertner R, et al. Distinct requirements for IFNs and STAT1 in NK cell function. J Immunol 2000; 165(7):3571-3577.
32. Fuggetta MP, Graziani G, Aquino A, et al. Effect of hydrocortisone on human natural killer activity and its modulation by beta interferon. Int J Immunopharmacol 1988; 10(6):687-694.
33. Avraham R, Schwartz Y, Rosenne E, et al. IL-12-based immunotherapy reduces post-surgery immunosuppression and metastasis, and increases survival from experimental leukemia. Psychoneuroimmunology Research Society, Vol. 18, Brain Behav Immun Titisee Germany: Elsevier; 2004.
34. Faist E, Schinkel C, Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg 1996; 20(4):454-459.
35. Leung KH, Koren HS. Regulation of human natural killing. III. Mechanism for interferon induction of loss of susceptibility to suppression by cyclic AMP elevating agents. J Immunol 1984; 132(3):1445-1450.
36. Brittenden J, Heys SD, Ross J, Eremin O. Natural killer cells and cancer. Cancer 1996; 77(7):1226-1243.
37. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000; 164(4):2214-2220.
38. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2(4):293-299.
39. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411(6835):380-384.
40. Giantonio BJ, Hochster H, Blum R, et al. Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Invest New Drugs 2001; 19(1):89-92.
41. Salazar AM, Levy HB, Ondra S, et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 1996; 38(6):1096-1104.